Accès ouvert
2026
preprint
OpenAlex
Mikalai Katsin, Valeria M. Stepanova, Dmitri Dormeshkin, Alexandr A. Migas et autres
Abstract Background CD19-directed CAR-T cell therapy can induce durable remissions in chronic lymphocytic leukemia (CLL), but response rates are lower than in other B-cell malignancies, in part because CLL is characterized by T-cell dysfunction, defective immune synapse formation, and impaired target-cell co-stimulation. …
by, ru, us
(code pays fourni par la source)
Accès ouvert
2025
conference-abstract
OpenAlex
Mikalai Katsin, Dmitri Dormeshkin, Alexandr A. Migas, Yuliya Serada et autres
Abstract Introduction Despite the clinical efficacy of CD19 CAR-T cells in Non-Hodgkin lymphomas, the clinical efficacy of CD19 CAR T-cell therapy in chronic lymphocytic leukemia (CLL) is at least two times lower. The inability to establish immunological synapses, along with low levels …
by, us, ru
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Mikalai Katsin, Dmitri Dormeshkin, Alexandr A. Migas, Т. В. Шман et autres
= 0.0416); however, no clear advantage in PFS was observed. BY19's safety and efficacy profiles were comparable to approved CD19 CAR T cell products. This study underscores the translational potential of localized CAR T cell manufacturing to expand global access to advanced …
by
(code pays fourni par la source)
Accès ouvert
2025
preprint
OpenAlex
Mikalai Katsin, Dmitri Dormeshkin, Alexandr A. Migas, Т. В. Шман et autres
Abstract Despite the approval of multiple CAR T-cell products, access to this therapy remains limited in many developing countries. We conducted a single-arm, open-label, non-randomized, parallel phase 1/2 clinical trial ( ClinicalTrials.gov identifier: NCT05333302 ) at two independent centers: the Vitebsk Regional …
us, by
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Mikalai Katsin, Т. В. Шман, Alexandr A. Migas, Dzmitry V. Lutskovich et autres
Corticosteroid therapy is the mainstay of immune effector cell-associated neurotoxicity syndrome (ICANS) management, although its use has been associated with worse overall survival (OS) and progression-free survival (PFS) after chimeric antigen receptor T-cell (CAR-T cell) therapy. Many options are being investigated for …
by
(code pays fourni par la source)